Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines

被引:43
作者
Gravekamp, C
Kasper, DL
Paoletti, LC
Madoff, LC
机构
[1] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Dept Mol Genet & Microbiol, Boston, MA 02115 USA
关键词
D O I
10.1128/IAI.67.5.2491-2496.1999
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The alpha C protein, a protective surface protein of group B streptococci (GBS), is present in most non-type III GBS strains. Conjugate vaccines composed of the alpha C protein and type III capsular polysaccharide (CPS) might be protective against most GBS infections. In this study, the type III CPS was covalently coupled to full-length, nine-repeat alpha C protein (resulting in III-alpha 9r conjugate vaccine) or to two-repeat alpha C protein (resulting in III-alpha 2r conjugate vaccine) by reductive amination, Initial experiments with the III-alpha 9r vaccine showed that it was poorly immunogenic in mice with respect to both vaccine antigens and was suboptimally efficacious in providing protection in mice against challenge with GBS, Therefore, modified vaccination protocols were used with the III-alpha 2r vaccine. Female mice were immunized three times with 0.5, 5, or 20 mu g of the III-alpha 2r vaccine with an aluminum hydroxide adjuvant and bred. Ninety-five percent of neonatal mice born to dams immunized with the III-alpha 2r vaccine survived challenge with GBS expressing type III CPS, and 60% survived challenge with GBS expressing wild-type (nine-repeat) alpha C protein; 18 and 17%, respectively, of mice in the negative control groups survived (P, <0.0001). These protection levels did not differ significantly from those obtained with the type III CPS-tetanus toroid conjugate vaccine and the unconjugated two repeat alpha C protein, which protected 98 and 58% of neonates from infection with GBS expressing type III CPS or the alpha C protein, respectively. Thus, the two-repeat alpha C protein in the vaccine was immunogenic and simultaneously enhanced the immunogenicity of type III CPS, III-alpha vaccines may be alternatives to GBS polysaccharide-tetanus toroid vaccines, eliciting additional antibodies protective against GBS infection.
引用
收藏
页码:2491 / 2496
页数:6
相关论文
共 39 条
[11]   MOLECULAR-SPECIES OF R-PROTEIN ANTIGENS PRODUCED BY CLINICAL ISOLATES OF GROUP-B STREPTOCOCCI [J].
FLORES, AE ;
FERRIERI, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (05) :1050-1054
[12]  
Gravekamp C, 1998, INFECT IMMUN, V66, P4347
[13]   Variation in repeat number within the alpha C protein of group B streptococci alters antigenicity and protective epitopes [J].
Gravekamp, C ;
Horensky, DS ;
Michel, JL ;
Madoff, LC .
INFECTION AND IMMUNITY, 1996, 64 (09) :3576-3583
[14]   Immunogenicity and protective efficacy of the alpha C protein of group B streptococci are inversely related to the number of repeats [J].
Gravekamp, C ;
Kasper, DL ;
Michel, JL ;
Kling, DE ;
Carey, V ;
Madoff, LC .
INFECTION AND IMMUNITY, 1997, 65 (12) :5216-5221
[15]   Quantitative determination of antibodies to type III group B streptococcal polysaccharide [J].
Guttormsen, HK ;
Baker, CJ ;
Edwards, MS ;
Paoletti, LC ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :142-150
[16]   Immunologic memory induced by a glycoconjugate vaccine in a murine adoptive lymphocyte transfer model [J].
Guttormsen, HK ;
Wetzler, LM ;
Finberg, RW ;
Kasper, DL .
INFECTION AND IMMUNITY, 1998, 66 (05) :2026-2032
[17]  
GUTTORMSEN HK, COMMUNICATION
[18]   CARRIER-PRIMING LEADS TO HAPTEN-SPECIFIC SUPPRESSION [J].
HERZENBERG, LA ;
TOKUHISA, T ;
HERZENBERG, LA .
NATURE, 1980, 285 (5767) :664-667
[19]   GROUP-B STREPTOCOCCAL-IBC PROTEIN ANTIGEN - DISTRIBUTION OF 2 DETERMINANTS IN WILD-TYPE STRAINS OF COMMON SEROTYPES [J].
JOHNSON, DR ;
FERRIERI, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1984, 19 (04) :506-510
[20]   Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine [J].
Kaspar, DL ;
Paoletti, LC ;
Wessels, MR ;
Guttormsen, HK ;
Carey, VJ ;
Jennings, HJ ;
Baker, CJ .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (10) :2308-2314